BABrynn N. Akerberg

Brynn N. Akerberg

*This is an algorithmically generated author record based on publicly available information.

Brynn N. Akerberg has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • William T. Pu

    Department of Cardiology, Boston Children's Hospital, Boston, MA, USA.

    4 shared publications
  • Alla A. Sigova

    CAMP4 Therapeutics Corp., Cambridge, MA USA

    2 shared publications
  • Bin Zhou

    CAS CEMCS-CUHK Joint Laboratory, New Cornerstone Science Laboratory, Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    2 shared publications
  • David Bumcrot

    CAMP4 Therapeutics Corp., Cambridge, MA USA

    2 shared publications
  • Fei Gu

    Department of Cardiology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA

    2 shared publications
  • Gabriel Golczer

    CAMP4 Therapeutics Corp., Cambridge, MA USA

    2 shared publications

Latest Publications

  • Open Access

    Antisense Oligonucleotides Targeting an LDLR Regulatory RNA Increase LDLR Expression and Reduce LDL-cholesterol in Vivo

    by Keerthana Gnanapradeepan, Salomé Manska, Brian Schwartz, Gabriel Golczer, Jiaqi Huang, Rachana S. Kelkar, Andrew Masteller, Shama Pilankar, Marianne Richter, Scott Waldron, et al.

    Regulatory RNAs (regRNAs) are non-coding RNAs expressed from promoters and enhancers that modulate gene transcription. Targeting regRNAs with antisense oligonucleotides (ASOs) can increase transcription and presents a potential therapeutic strategy to restore expression in haploinsufficient diseases. This approach requires high-quality regRNA maps, identification of ASOs targeting actionable sequences, and translation of efficacy to relevant animal models. Here, we describe this approach for human low-density lipoprotein receptor ( LDLR ). We characterized LDLR regRNAs in HepG2 cells and human liver using epigenomic mapping and regRNA Capture-seq, and designed ASOs targeting these regRNAs. Several ASOs increased LDLR expression in cells and a lead was evaluated for efficacy in a humanized liver mouse model. ASO administration increased human LDLR mRNA and protein, while lowering LDL-cholesterol in plasma. These data provide a framework for the discovery and translation of ASOs that increase gene expression as a potential therapeutic approach for the treatment of haploinsufficient diseases.

  • Open Access

    Profiling and Targeting of Regulatory RNAs to Upregulate Gene Expression

    by Brynn N. Akerberg, Bryan J. Matthews, Yuting Liu, Cecile Mathieu, Jenna Williams, Salome Manska, Jiaqi Huang, Yuichi Nishi, Abeer Almutairy, Eric Coughlin, et al.

    Transcription of long noncoding RNAs (lncRNAs), including enhancer RNAs (eRNAs) and promoter-associated RNAs (paRNAs), collectively termed regulatory RNAs (regRNAs), is a hallmark of active gene expression, yet it remains unknown whether regRNAs can be targeted to selectively enhance transcription in cis . We developed regRNA Capture-seq, a high-throughput method to profile regRNAs, and applied it to primary human hepatocytes, annotating thousands of regRNAs at ∼2,000 enhancers and promoters. Using this approach, we interrogated a genetically validated enhancer of the ornithine transcarbamylase ( OTC ) gene, mutations of which cause OTC deficiency (OTCD), the most common urea cycle disorder. Antisense oligonucleotides (ASOs) targeting enhancer-derived regRNAs led to dose-dependent upregulation of OTC in hepatocytes. Mechanistically, ASOs altered regRNA structure, elevated regRNA levels, displaced transcriptional repressors, and increased H3K27 acetylation at the targeted enhancer. This work establishes a potential therapeutic strategy for addressing haploinsufficiency and highlights regRNAs as actionable targets for ASO-mediated upregulation of gene expression.


  • Open Access

    YAP/TEAD1 Complex Is a Default Repressor of Cardiac Toll-Like Receptor Genes

    by Yunan Gao, Yan Sun, Adife Gulhan Ercan-Sencicek, Justin S. King, Brynn N. Akerberg, Qing Ma, Maria I. Kontaridis, William T. Pu, Zhiqiang Lin

    Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) that modulate innate immune responses and play essential roles in the pathogenesis of heart diseases. Although important, the molecular mechanisms controlling cardiac TLR genes expression have not been clearly addressed. This study examined the expression pattern of Tlr1, Tlr2, Tlr3, Tlr4, Tlr5, Tlr6, Tlr7, Tlr8, and Tlr9 in normal and disease-stressed mouse hearts. Our results demonstrated that the expression levels of cardiac Tlr3, Tlr7, Tlr8, and Tlr9 increased with age between neonatal and adult developmental stages, whereas the expression of Tlr5 decreased with age. Furthermore, pathological stress increased the expression levels of Tlr2, Tlr4, Tlr5, Tlr7, Tlr8, and Tlr9. Hippo-YAP signaling is essential for heart development and homeostasis maintenance, and YAP/TEAD1 complex is the terminal effector of this pathway. Here we found that TEAD1 directly bound genomic regions adjacent to Tlr1, Tlr2, Tlr3, Tlr4, Tlr5, Tlr6, Tlr7, and Tlr9. In vitro, luciferase reporter data suggest that YAP/TEAD1 repression of Tlr4 depends on a conserved TEAD1 binding motif near Tlr4 transcription start site. In vivo, cardiomyocyte-specific YAP depletion increased the expression of most examined TLR genes, activated the synthesis of pro-inflammatory cytokines, and predisposed the heart to lipopolysaccharide stress. In conclusion, our data indicate that the expression of cardiac TLR genes is associated with age and activated by pathological stress and suggest that YAP/TEAD1 complex is a default repressor of cardiac TLR genes.


  • Open Access

    Modeling human TBX5 haploinsufficiency predicts regulatory networks for congenital heart disease

    by Irfan Shiraz Kathiriya, Kavitha S. Rao, Giovanni Iacono, W. Patrick Devine, Andrew P. Blair, Swetansu K. Hota, Michael H. Lai, Bayardo I. Garay, Reuben Thomas, Henry Z. Gong, et al.

    Haploinsufficiency of transcriptional regulators causes human congenital heart disease (CHD). However, underlying CHD gene regulatory network (GRN) imbalances are unknown. Here, we define transcriptional consequences of reduced dosage of the CHD-linked transcription factor, TBX5, in individual cells during cardiomyocyte differentiation from human induced pluripotent stem cells (iPSCs). We discovered highly sensitive dysregulation of TBX5-dependent pathways— including lineage decisions and genes associated with cardiomyocyte function and CHD genetics—in discrete subpopulations of cardiomyocytes. GRN analysis identified vulnerable nodes enriched for CHD genes, indicating that cardiac network stability is sensitive to TBX5 dosage. A GRN-predicted genetic interaction between Tbx5 and Mef2c was validated in mouse, manifesting as ventricular septation defects. These results demonstrate exquisite sensitivity to TBX5 dosage by diverse transcriptional responses in heterogeneous subsets of iPSC-derived cardiomyocytes. This predicts candidate GRNs for human CHDs, with implications for quantitative transcriptional regulation in disease.


  • Open Access

    A reference map of murine cardiac transcription factor chromatin occupancy identifies dynamic and conserved enhancers

    by Brynn N. Akerberg, Fei Gu, Nathan J. VanDusen, Xiaoran Zhang, Rui Dong, Kai Li, Bing Zhang, Bin Zhou, Isha Sethi, Qing Ma, et al.

    Mapping the chromatin occupancy of transcription factors (TFs) is a key step in deciphering developmental transcriptional programs. Here we use biotinylated knockin alleles of seven key cardiac TFs (GATA4, NKX2-5, MEF2A, MEF2C, SRF, TBX5, TEAD1) to sensitively and reproducibly map their genome-wide occupancy in the fetal and adult mouse heart. These maps show that TF occupancy is dynamic between developmental stages and that multiple TFs often collaboratively occupy the same chromatin region through indirect cooperativity. Multi-TF regions exhibit features of functional regulatory elements, including evolutionary conservation, chromatin accessibility, and activity in transcriptional enhancer assays. H3K27ac, a feature of many enhancers, incompletely overlaps multi-TF regions, and multi-TF regions lacking H3K27ac retain conservation and enhancer activity. TEAD1 is a core component of the cardiac transcriptional network, co-occupying cardiac regulatory regions and controlling cardiomyocyte-specific gene functions. Our study provides a resource for deciphering the cardiac transcriptional regulatory network and gaining insights into the molecular mechanisms governing heart development.


  • Open Access

    Mapping cell type-specific transcriptional enhancers using high affinity, lineage-specific Ep300 bioChIP-seq

    by Pingzhu Zhou, Fei Gu, Lina Zhang, Brynn N Akerberg, Qing Ma, Kai Li, Aibin He, Zhiqiang Lin, Sean M Stevens, Bin Zhou, et al.

    Understanding the mechanisms that regulate cell type-specific transcriptional programs requires developing a lexicon of their genomic regulatory elements. We developed a lineage-selective method to map transcriptional enhancers, regulatory genomic regions that activate transcription, in mice. Since most tissue-specific enhancers are bound by the transcriptional co-activator Ep300, we used Cre-directed, lineage-specific Ep300 biotinylation and pulldown on immobilized streptavidin followed by next generation sequencing of co-precipitated DNA to identify lineage-specific enhancers. By driving this system with lineage-specific Cre transgenes, we mapped enhancers active in embryonic endothelial cells/blood or skeletal muscle. Analysis of these enhancers identified new transcription factor heterodimer motifs that likely regulate transcription in these lineages. Furthermore, we identified candidate enhancers that regulate adult heart- or lung- specific endothelial cell specialization. Our strategy for tissue-specific protein biotinylation opens new avenues for studying lineage-specific protein-DNA and protein-protein interactions.